Innovating Works

INFORMATION TECHNOLOGY FOR TRANSLATIONAL...

Desconocido
SYNTHIA: Synthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare Applica... SYNTHIA is an ambitious collaboration between public and private institutions to facilitate the responsible use of Synthetic Data (SD) in he...
2024-08-09 - 2029-08-31 | Financiado
IDERHA: Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced...
2023-05-10 - 2028-03-31 | Financiado
OPTIMA: Optimal treatment for patients with solid tumours in Europe through Artificial intelligence INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individua...
2021-10-18 - 2026-09-30 | Financiado
T2EVOLVE: Accelerating Development and Improving Access to CAR and TCR engineered T cell therapy INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative...
2020-11-24 - 2025-12-31 | Financiado
ICU4Covid: Cyber Physical Intensive Care Medical System for Covid 19 INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un H2020: H2020-SC1-PHE-CORONAVIRUS-2020-2 The European health services have well responded to the COVID-19 emerging crisis, especially if and where the intensive care unit (ICU) capa...
2020-10-13 - 2022-12-31 | Financiado
ImmUniverse: Better control and treatment of immune mediated diseases by exploring the universe of microenvironme... INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enorm...
2019-12-17 - 2024-12-31 | Financiado
EU-PEARL: EU Patient cEntric clinicAl tRial pLatform INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company I...
2019-11-27 - 2023-04-30 | Financiado
imSAVAR: Immune Safety Avatar nonclinical mimicking of the immune system effects of immunomodulatory therapi... INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy saf...
2019-11-18 - 2025-11-30 | Financiado
TransBioLine: Translational Safety Biomarker Pipeline TransBioLine Enabling development and implementation of n... INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Qualified biomarkers help to optimize drug development and patient safety, yet for the regulatory acceptance of safety biomarkers substantia...
2019-04-08 - 2025-01-31 | Financiado
BIOMAP: Biomarkers in Atopic Dermatitis and Psoriasis INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molec...
2019-02-27 - 2025-03-31 | Financiado
Smart4Health: Citizen centred EU EHR exchange for personalised health INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un H2020: H2020-SC1-DTH-2018-2020 Smart4Health will enable the citizen-centred EU EHR exchange for personalised health. This will pave the way for the full deployment of citi...
2018-12-06 - 2023-10-31 | Financiado
GLIOTRAIN: Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational... INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE ITTM SA participó en un H2020: H2020-MSCA-ITN-2017 Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patien...
2017-08-29 - 2021-08-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.